Last updated: September 8, 2026
MGL-3196, now marketed as Rezdiffra (resmetirom), is a first-in-class oral thyroid hormone receptor beta agonist developed by Madrigal Pharmaceuticals for metabolic dysfunction-associated steatohepatitis, or MASH, formerly called nonalcoholic steatohepatitis. The FDA approved Rezdiffra on March 14, 2024, for adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis, specifically stages F2 and F3, in combination with diet and exercise.[1]
The approval converted MGL-3196 from a late-stage development asset into a commercial product with an estimated U.S. peak-sales opportunity of approximately $4 billion to $7 billion. The principal risks are physician adoption, payer restrictions, diagnostic bottlenecks, long-term outcomes, competition from incretin-based therapies, and generic entry after the expiration of key patents.
What is MGL-3196 and how does resmetirom work?
MGL-3196 is the development code for resmetirom, a selective thyroid hormone receptor beta, or THR-beta, agonist.
THR-beta is expressed primarily in the liver. Resmetirom is designed to increase hepatic fatty-acid oxidation and reduce liver fat, dyslipidemia, inflammation and fibrosis-related disease activity without producing the systemic thyroid effects associated with nonselective thyroid hormone agonism.
| Attribute |
MGL-3196 / Rezdiffra |
| Active ingredient |
Resmetirom |
| Developer |
Madrigal Pharmaceuticals |
| Drug class |
Selective THR-beta agonist |
| Dosage form |
Oral tablet |
| Approved indication |
Noncirrhotic MASH with moderate-to-advanced fibrosis, F2-F3 |
| FDA approval |
March 14, 2024 |
| FDA pathway |
Accelerated approval |
| Recommended doses |
80 mg for patients under 100 kg; 100 mg for patients at least 100 kg |
| Treatment setting |
Used with diet and exercise |
| Primary target population |
Adults with MASH and fibrosis stages F2-F3 |
Rezdiffra is the first FDA-approved drug specifically indicated for MASH with liver fibrosis. Its approval created a new commercial category, although several metabolic and antifibrotic competitors remain in development.
What is the development status of MGL-3196?
MGL-3196 completed Phase 2 and Phase 3 development before receiving FDA approval.
Phase 2 development
Madrigal’s Phase 2 study evaluated resmetirom in patients with nonalcoholic fatty liver disease and suspected NASH. The study reported reductions in liver fat measured by magnetic resonance imaging and improvements in atherogenic lipid parameters. These findings supported progression into biopsy-based Phase 3 trials.
MAESTRO-NAFLD
The MAESTRO-NAFLD study evaluated liver-fat reduction and safety in patients with noncirrhotic nonalcoholic fatty liver disease. The study was designed primarily to provide supportive evidence for the regulatory program rather than serve as the principal histology-based registration trial.
MAESTRO-NASH
MAESTRO-NASH was the pivotal registration study. It enrolled patients with biopsy-confirmed NASH and fibrosis stages F1b through F3, with the approval-relevant population concentrated in F2 and F3 disease.
At 52 weeks, the trial met both key histologic endpoints:
- At least one-stage improvement in fibrosis without worsening of the NAFLD activity score.
- Resolution of steatohepatitis without worsening of fibrosis.
The FDA accepted these histologic endpoints as reasonably likely to predict clinical benefit under the accelerated-approval framework.[1][2]
MAESTRO-NASH-OUTCOMES
Madrigal is conducting a confirmatory outcomes study in patients with compensated MASH cirrhosis. The study is intended to establish whether resmetirom reduces progression to liver-related clinical events, including hepatic decompensation and other serious liver outcomes.
The confirmatory trial is strategically important because continued approval depends on verification of clinical benefit. A failure to confirm benefit could create regulatory risk even though the current indication remains commercially significant.
What is the FDA regulatory status of Rezdiffra?
Rezdiffra has FDA accelerated approval for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis consistent with F2-F3 disease.[1]
The approval does not cover:
- Decompensated cirrhosis.
- All patients with fatty liver disease.
- Patients without meaningful fibrosis.
- Pediatric MASH.
- A general cardiovascular or weight-loss indication.
The FDA label includes important drug-interaction and safety considerations. Resmetirom can affect thyroid hormone pathways and has clinically relevant interactions with statins. The label also warns of hepatotoxicity and gallbladder-related adverse events.[3]
What is the regulatory status outside the United States?
As of the FDA approval period, the United States was the first major market to approve resmetirom for MASH. Expansion into Europe, Japan and other territories represents a separate regulatory and commercial opportunity. Madrigal’s international strategy is likely to depend on regulatory acceptance of the histologic endpoint package, local pricing controls and the economics of specialty hepatology distribution.
When does MGL-3196 lose exclusivity?
The effective loss-of-exclusivity date depends on the specific patent, patent-term adjustment, pediatric extension, litigation outcome and any settlement with generic applicants.
Madrigal’s protection is expected to rely on a layered portfolio covering:
- Resmetirom composition and chemical structure.
- Pharmaceutical compositions and dosage forms.
- Treatment of MASH, NASH and related liver diseases.
- Patient-selection criteria based on fibrosis or disease characteristics.
- Dosing and administration methods.
- Manufacturing and solid-state properties.
The earliest composition-of-matter protection is generally more important than later method-of-use patents because an approved generic may challenge use patents while relying on a skinny label. Later patents can still delay commercial entry if they cover the marketed indication or a commercially necessary formulation.
A reasonable commercial planning assumption is that U.S. generic entry risk is limited before the mid-to-late 2030s, subject to patent litigation and the scope of Orange Book-listed patents. Patent-term extensions could affect the final date. The practical exclusivity period may be shorter than the nominal patent term if generic companies file Paragraph IV challenges several years before expiration.
What is the Orange Book status of Rezdiffra?
Rezdiffra is an FDA-approved small-molecule product that can support Orange Book patent listings. It is not a biologic and therefore does not receive a biosimilar pathway under the Public Health Service Act.
The relevant competitive pathway is an abbreviated new drug application, or ANDA, rather than a biosimilar application. A generic applicant could challenge listed patents through a Paragraph IV certification.
Orange Book risk will depend on:
- Which patents Madrigal lists for the approved product.
- Whether those patents cover the active ingredient, tablet formulation or approved use.
- Whether a generic applicant can design around formulation claims.
- Whether a Paragraph IV notice triggers litigation.
- Whether a 30-month stay delays ANDA approval.
- Whether Madrigal reaches a settlement providing an agreed entry date.
The composition and active-ingredient claims are likely to be the strongest barriers. Method-of-use claims may be more vulnerable if a generic applicant proposes a label that omits patented uses, although the commercial relevance of a narrow label depends on prescribing practice.
Which companies are challenging MGL-3196?
No biosimilar challenger is relevant because resmetirom is a conventional small molecule. The main future challengers are likely to be generic manufacturers with experience in specialty oral drugs and liver therapies.
Potential generic entrants could include:
- Teva Pharmaceuticals.
- Sandoz.
- Viatris.
- Dr. Reddy’s Laboratories.
- Sun Pharmaceutical Industries.
- Lupin.
- Zydus Lifesciences.
- Amneal Pharmaceuticals.
The timing of actual challenges is unknown until an ANDA filer submits a Paragraph IV certification. A realistic challenge window could open several years before the earliest relevant patent expiration because generic companies often file early to secure market position.
What formulation patents protect Rezdiffra?
The commercial product is an oral tablet available in 80 mg and 100 mg strengths. Formulation protection may cover:
- Tablet composition.
- Resmetirom particle characteristics.
- Stability and dissolution performance.
- Solid-state or polymorphic forms.
- Manufacturing process controls.
- Dose-specific tablet design.
Formulation patents usually provide secondary protection rather than replacing composition-of-matter protection. They can be commercially valuable if the formulation delivers a required bioavailability profile or if a generic cannot readily reproduce the product without infringing.
The principal manufacturing barrier is unlikely to be biologic complexity. Resmetirom is a chemically synthesized small molecule. The more material barriers are likely to involve process reproducibility, impurity control, formulation stability and regulatory equivalence.
What patent litigation and settlement risks affect Rezdiffra?
No major public Paragraph IV litigation affecting Rezdiffra was established at the time of FDA approval. Litigation risk should increase as the product approaches broader market penetration and generic companies evaluate the size of the opportunity.
A typical future dispute could involve:
- Validity of composition patents.
- Obviousness based on earlier thyroid-hormone research.
- Written-description and enablement issues.
- Infringement of method-of-use claims.
- Patent-term adjustment calculations.
- Product-by-process or formulation claims.
- The scope of any approved generic label.
A settlement could permit a generic launch before the last asserted patent expires. The economic value of such a settlement would depend on whether entry is exclusive, whether multiple generics can enter simultaneously and whether the settlement includes authorized-generic rights.
What is the commercial market projection for resmetirom?
The commercial market is large because MASH is prevalent, progressive disease is underdiagnosed and no previously approved antifibrotic therapy existed. The initial market is constrained by the requirement for fibrosis staging and by the limited number of hepatologists and gastroenterologists experienced in treating MASH.
Madrigal reported a U.S. wholesale acquisition cost of approximately $47,400 per patient per year at launch.[4]
Resmetirom revenue scenarios
| Scenario |
Treated U.S. patients at maturity |
Net annual price assumption |
Estimated annual sales |
| Conservative |
75,000 |
$35,000 |
$2.6 billion |
| Base case |
125,000 |
$35,000-$40,000 |
$4.4 billion-$5.0 billion |
| Upside |
175,000 |
$40,000 |
$7.0 billion |
These figures are scenario estimates, not company guidance. Gross WAC is higher than the net price after rebates, discounts, patient assistance and payer concessions.
The base case assumes that resmetirom becomes the standard pharmacologic treatment for a substantial portion of diagnosed F2-F3 patients. The upside case requires broader diagnosis, favorable long-term outcomes, effective primary-care referral and limited displacement by competing metabolic agents.
How does resmetirom compare with competing MASH drugs?
Resmetirom has the advantage of being first to market with an approved MASH indication. Its principal competitors are either investigational drugs or therapies approved for adjacent conditions.
| Therapy |
Developer |
Mechanism |
Development or market position |
| Rezdiffra / resmetirom |
Madrigal |
THR-beta agonist |
FDA-approved for F2-F3 MASH |
| Semaglutide |
Novo Nordisk |
GLP-1 receptor agonist |
Strong weight-loss and metabolic profile; MASH development relevance |
| Tirzepatide |
Eli Lilly |
GIP/GLP-1 receptor agonist |
Weight loss and metabolic benefits; potential liver-disease application |
| Lanifibranor |
Inventiva |
Pan-PPAR agonist |
Investigational antifibrotic approach |
| Selonsertib |
Formerly Gilead |
ASK1 inhibitor |
Prior late-stage failure |
| Obeticholic acid |
Intercept |
FXR agonist |
Failed to secure U.S. approval for NASH |
Resmetirom is differentiated by its direct liver mechanism and histology-based approval. GLP-1 and GIP/GLP-1 therapies may compete indirectly by reducing obesity, insulin resistance and liver fat. If those drugs demonstrate strong fibrosis or outcomes benefits, they could reduce the addressable population for resmetirom or become combination partners.
What generic launch scenarios exist for MGL-3196?
Three launch scenarios are commercially relevant.
Scenario 1: Delayed generic entry
Madrigal successfully defends core patents and generic entry occurs near the final patent expiration. This would preserve high-value revenue for most of the product’s life cycle.
Scenario 2: Settled early entry
Madrigal settles Paragraph IV litigation and permits one or more generics to enter before the final patent expiration. This could reduce net price and volume while allowing Madrigal to avoid litigation costs.
Scenario 3: Invalidity or noninfringement decision
A court invalidates a key patent or finds that the generic does not infringe. Multiple generic entrants could then launch, producing rapid price erosion. For a small-molecule specialty product, first-year price declines could range from 30% to more than 70%, depending on the number of entrants and payer behavior.
What is the investment outlook for Madrigal and resmetirom?
Resmetirom provides Madrigal with a single-product commercial platform and a potentially multibillion-dollar market. The investment case depends on five variables:
- Speed of diagnosis and fibrosis staging.
- Payer coverage and prior-authorization requirements.
- Persistence of treatment.
- Confirmatory outcomes data.
- Competitive pressure from obesity and metabolic drugs.
Revenue concentration is high because Madrigal’s commercial exposure is centered on Rezdiffra. Strong launch execution could support rapid valuation expansion, while poor persistence, restrictive reimbursement or negative outcomes data would have an outsized impact.
Key Takeaways
- MGL-3196 is resmetirom, marketed in the United States as Rezdiffra.
- The FDA approved Rezdiffra on March 14, 2024, for adults with noncirrhotic F2-F3 MASH.
- Approval was based on histologic improvements in the MAESTRO-NASH program under the accelerated-approval pathway.
- Madrigal must complete confirmatory outcomes work to verify clinical benefit.
- The product is a small molecule, so future competition will involve ANDAs and Paragraph IV patent challenges, not biosimilars.
- Estimated U.S. peak sales range from approximately $4 billion to $7 billion, with a base case near $5 billion.
- Patent protection is expected to extend into the mid-to-late 2030s, subject to patent scope, term adjustments, litigation and settlements.
- The largest commercial constraints are diagnosis, fibrosis staging, reimbursement and competition from metabolic therapies.
FAQs
Is MGL-3196 the same as Rezdiffra?
Yes. MGL-3196 is the development code for resmetirom, and Rezdiffra is the approved U.S. brand name.
Is resmetirom a biologic or a biosimilar?
No. Resmetirom is a chemically synthesized small molecule. Generic competition will proceed through the ANDA pathway.
Can Rezdiffra treat all patients with fatty liver disease?
No. The FDA indication is limited to adults with noncirrhotic MASH and moderate-to-advanced fibrosis consistent with F2-F3 disease.
What could reduce resmetirom sales?
The main risks are slow diagnosis, payer restrictions, treatment discontinuation, unfavorable confirmatory outcomes data and competition from GLP-1 or GIP/GLP-1 therapies.
Does resmetirom have a cirrhosis indication?
No. Rezdiffra’s initial FDA indication does not cover decompensated cirrhosis. Madrigal is studying resmetirom in compensated MASH cirrhosis.
References
-
U.S. Food and Drug Administration. (2024, March 14). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
-
Harrison, S. A., Bedossa, P., Guy, C. D., et al. (2024). A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New England Journal of Medicine.
-
U.S. Food and Drug Administration. (2024). Rezdiffra (resmetirom) prescribing information. Madrigal Pharmaceuticals.
-
Madrigal Pharmaceuticals, Inc. (2024). Annual report and commercial launch disclosures for Rezdiffra. Form 10-K and investor materials.
